Genetics of Cushing's Syndrome



Laura C. Hernández-Ramírez, MD, PhD, Constantine A. Stratakis, MD, D(Med)Sci*

KEYWORDS

- Cushing's syndrome Glucocorticoids ACTH Corticotropinoma
- Pituitary adenoma
 Adrenal hyperplasia
 cAMP
 USP8

KEY POINTS

- Cushing's syndrome (CS) of pituitary or adrenal origin usually presents as a sporadic entity and is most commonly due to somatic gene defects.
- Cortisol-producing adenomas are the most common cause of adrenal CS and these lesions are frequently caused by somatic activating mutations in the *PRKACA* gene.
- Somatic gain-of-function mutations in the USP8 gene constitute the most common genetic defect in corticotropinomas.
- Although infrequent, familial forms of CS may present either isolated or in association with various familial syndromes of multiple endocrine and nonendocrine neoplasia.
- Understanding the genetic defects that drive corticotroph and adrenocortical tumorigenesis should lead to unraveling novel therapeutic targets, which will hopefully be translated into more efficient strategies for the medical treatment of patients with CS.

INTRODUCTION

Characterized by multisystemic manifestations of hypercortisolemia, endogenous Cushing's syndrome (CS) is caused in two-thirds of cases by an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma (corticotropinoma), and in up to one-quarter of cases by benign adrenal lesions, whereas other causes are more infrequent. CS may have a familial presentation, as part of various syndromes of multiple neoplasia, or present sporadically in the presence of specific germline and/or somatic gene defects (Table 1). Vast progress has been achieved in recent years on identifying the molecular and genetic causes of CS of adrenal and pituitary (Cushing's disease [CD]) origin. In this review, we have compiled and summarized the most relevant genetic causes of adrenal and pituitary CS so far described.

Disclosure: The authors have nothing to disclose.

Section on Endocrinology and Genetics (SEGEN), *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), 10 Center Drive, CRC, Room 1E-3216, Bethesda, MD 20892-1862, USA

* Corresponding author.

E-mail address: stratakc@mail.nih.gov

Endocrinol Metab Clin N Am 47 (2018) 275–297 https://doi.org/10.1016/j.ecl.2018.02.007 0889-8529/18/Published by Elsevier Inc.

Origin	Lesion Type	General Molecular Mechanisms	Clinical Presentation	Known Genetic Causes
Cushing's disease (60%–70% of cases)	Corticotropinoma	Resistance to glucocorticoid negative feedback, cell-cycle dysregulation, overexpression of membrane receptors (arginine-vasopressin	Sporadic Cushing's disease, no associated manifestations	Somatic <i>USP8</i> GOF hotspot mutations Somatic <i>GNAS</i> GOF mutations (codon 201 or 227) Somatic <i>RASD1</i> LOF mutation
		receptors, epidermal growth factor receptor)	Carney complex	Germline PRKAR1A LOF mutations/deletions, uncharacterized defect in 2p16, PRKACB amplification
			Familial isolated pituitary adenoma	Germline AIP LOF mutations/ deletions, unknown genetic defect in 80% of cases
			Familial Cushing's disease with very low penetrance?	Germline CABLES1 LOF mutations
			Multiple endocrine neoplasia type 1	Germline <i>MEN1</i> LOF mutation deletions
			Multiple endocrine neoplasia type 2	Germline RET GOF mutations
			Pheoromocytoma/ paraganglioma and pituitary adenoma	
			Multiple endocrine neoplasia type 4	Germline CDKN1B LOF mutations/deletions
			Tuberous sclerosis	Germline TSC1 or TSC2 LOF mutations

Download English Version:

https://daneshyari.com/en/article/8722606

Download Persian Version:

https://daneshyari.com/article/8722606

<u>Daneshyari.com</u>